Shanghai Henlius Biotech...announced that the new drug application (NDA) for new indication of its self-developed innovative anti-PD-1 monoclonal antibody (mAb) HANSIZHUANG (serplulimab), in combination with pemetrexed and carboplatin for the first-line treatment of patients with unresectable locally advanced or metastatic non-squamous non-small cell lung cancer (nsNSCLC) who are negative for epidermal growth factor receptor (EGFR) gene mutation and anaplastic lymphoma kinase (ALK), has been approved by the National Medical Products Administration (NMPA).